ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2017.4737 ETM-0-0-4737 Articles Asymptomatic pulmonary tuberculosis mimicking lung cancer on imaging: A retrospective study LangShan 1 * SunJunping 1 * WangXuning 2 * XiaoYongjiu 1 * WangJuan 1 * ZhangMingyue 1 * AoTing 1 * WangJianxin 1 * Department of Respiratory Diseases, Chinese PLA General Hospital, Beijing 100853, P.R. China Department of Surgical Oncology, Chinese PLA General Hospital, Beijing 100853, P.R. China Correspondence to: Professor Jianxin Wang, Department of Respiratory Diseases, Chinese PLA General Hospital, 28 Fuxing Road, Haidian, Beijing 100853, P.R. China, E-mail: wangjianxin301@yeah.com

Contributed equally

 09 2017 09 07 2017 14 3 2180 2188 24072016 05052017 Copyright: © Lang et al. 2017 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Asymptomatic pulmonary tuberculosis (PTB) mimicking lung cancer is rare and has been documented in few studies. Accurately diagnosing this atypical disease remains an enormous challenge for clinicians. The aim of the present study was to characterize asymptomatic patients with PTB who were initially diagnosed with lung cancer according to their chest computer tomography (CT) or whole-body 18F-fludeoxyglucose-positron emission tomography-computer tomography (PET-CT) presentations. The clinical characteristics and radiographic features of patients with PTB were analyzed and compared to those of patients with lung cancer. In patients with PTB, all lesions exhibited suspected malignant signs on chest CT and the maximum standard uptake value (SUVmax) of PET-CT imaging was between 2.65 and 10.9. Compared with lung cancer, the factors associated with PTB included an age <60 years (82% vs. 46%, P=0.03), being male (77% vs. 51%, P=0.025), the presence of diabetes (55% vs. 16%, P<0.01), spiculated margins (82% vs. 44%, P=0.002) and a lower SUVmax (P=0.036). The optimal cut-off level was SUVmax 8.45 for discriminating between PTB and lung cancer. At this point, the sensitivity and specificity were 63.0 and 88.9%, respectively. The results of the current study revealed methods of distinguishing between the two similar diseases. Furthermore, the results of the current study may increase awareness that although imaging of lesions may resemble lung cancer, a diagnosis of PTB should be considered. Accurate diagnosis of PTB would mean that patients would be able to avoid undergoing unnecessary operations that induce a high financial burden.

 pulmonary tuberculosis lung cancer computed tomography positron emission tomography clinical characteristics early diagnosis Introduction

Tuberculosis remains a major cause of death worldwide despite a decline in incidence in recent years (1). It is estimated that there were 9.6 million new cases of tuberculosis and 1.5 million cases of tuberculosis-associated mortality in 2014. China, one of nine high-burden countries of tuberculosis, had 10% of the global total TB cases (2). Although the majority of exposed individuals have asymptomatic latent tuberculosis, they are at increased risk of developing active tuberculosis and becoming infectious (3). Asymptomatic pulmonary tuberculosis (PTB) exhibits various clinical and radiological features that resemble a number of other diseases (4,5). Cases of PTB that mimic lung cancer are encountered on occasion. According to a report from National Central Cancer Registry of China, there were 651,053 newly diagnosed cases of lung cancer in 2011 in China, and 529,153 patients died of lung cancer with a crude incidence and mortality of 48.32 per 100,000 population and 39.27 per 100,000 population, respectively (6,7). Due to the increasing incidence and mortality of lung cancer, it has become the leading cause of cancer-related death in China (8). The clinical symptoms and radiologic features of PTB are nonspecific and resemble lung cancer, therefore accurate diagnosis of these two diseases remain a diagnostic dilemma in the clinic (9–13).

Typical manifestations of PTB are generally easy to diagnose due to defined clinical characteristics and radiographic findings. However, many symptoms of PTB, including cough, hemoptysis and weight loss are also common in lung cancer (14). Meanwhile, typical radiographic features indicating lung cancer, including thick-walled cavities and high fluorodeoxyglucose (FDG) uptake are also seen in PTB (11), and so patients exhibiting asymptomatic PTB mimicking lung cancer are often misdiagnosed with lung cancer. The misdiagnosis may result in delayed treatment for PTB and unnecessary operations, further increasing the severity and complications of PTB (15,16). Therefore, the present study was conducted in order to identify the features of this unusual PTB and improve the diagnostic accuracy.

 Patients and methods <sec> <title>Patients

A total of 1,487 individuals at Chinese PLA General Hospital (Beijing, China) were consecutively enrolled in the current study between January 2011 and December 2015. These individuals were included as they underwent a periodic health examination and an indeterminate lung nodule or mass was detected by chest X-ray. A total of 241 individuals were initially excluded due to the following reasons: 138 did not undergo further examination, 45 exhibited symptoms of PTB or lung cancer, 39 had a history of cancer or tuberculosis, 16 had undergone thoracic surgery in the past 6 months and 3 were <18 years old. Out of the 1,246 individuals who subsequently underwent chest computer tomography (CT) or whole-body 18F-fludeoxyglucose-positron emission tomography-computer tomography (PET-CT), 226 were presumptively diagnosed with lung cancer. No pathological examinations were performed in 112 individuals, the data for 7 individuals was missing and 4 individuals tested negative for lung cancer or PTB; these patients were all excluded. Therefore, 22 patients with PTB and 81 patients with lung cancer were included in the current study (Fig. 1). PTB diagnosis was established by pathological and acid-fast bacilli examinations. Briefly, tissue samples obtained from pulmonary lobectomy excision, percutaneous transthoracic needle biopsy or transbronchial lung biopsy were excised and fixed with 10% neutral buffered formalin at room temperature for 48 h. After fixation, the tissues were dehydrated and embedded in paraffin. Samples were then cut into 4 µm sections, stained with hematoxylin and eosin and examined using light microscopy (Olympus BX51; Olympus Corp. Tokyo, Japan). PTB lesions exhibited chronic granulomatous inflammation, with or without caseous necrosis. To further identified the mycobacteria in the tissue sections, acid-fast staining kits (Baso Biotechnology Co., Ltd., Wuhan, China) were used according to the manufacturer's protocol. Of the 22 patients with PTB, the mean age was 53.1±10.0 years (age range, 36–72 years) and there were more males (17/22, 77.3%) than females (5/22, 22.7%). The patients with lung cancer consisted of 41 males and 40 females with a mean age of 61±5.4 years (range, 33–79 years). The present study was approved by the Institutional Review Board of Chinese PLA General Hospital and written informed consents were waived as all the data were retrospectively reviewed and analyzed anonymously.

 Methods

The clinical data, radiological features, pathological results and therapeutic strategies of these patients were retrospectively reviewed. Clinical data included age, gender, smoking, medical history, histological type, tumor node metastasis (TNM) staging, performance status (PS) and levels of tumor markers. According to the 2015 World Health Organization (WHO) classifications of lung cancer (17), the histological types of lung cancer in the current study were determined. TNM staging of lung cancers was evaluated using the 7th edition of the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system (18). The PS of lung cancers was assessed using the Eastern Cooperative Oncology Group scale (19). Tumor marker values in the serum including carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21-1), neuron-specific enolase (NSE) and cancer antigen (CA)-125 were detected by electrochemiluminescence immunoassay using the Roche COBAS E601 analyzer (Roche Diagnostics GmbH, Mannheim, Germany). Squamous cell carcinoma antigen (SCCAg) was assayed using a chemiluminescence microparticle immunoassay (Abbott ARCHITECT i2000SR immuno analyser; Abbott Pharmaceutical Co., Ltd., Lake Bluff, IL, USA). Serum concentrations of CEA (cat. no. 153910-01; Roche Diagnostics GmbH), CYFRA21-1 (cat. no. 146987-02; Roche Diagnostics GmbH), NSE (cat. no. 159459-01; Roche Diagnostics GmbH), CA-125 (cat. no. 16907902; Roche Diagnostics GmbH) and SCCAg (cat. no. 71111LP20; Abbott Pharmaceutical Co., Ltd.) were measured using kits according to the manufacturer's protocol. Levels of CEA >5 ng/ml, CYFRA21-1 >4 ng/ml, NSE >24 ng/ml, CA-125 >35 ng/ml, SCCAg >1.8 ng/ml were considered to be abnormal according to the kit protocol. Radiological findings were based on the initial and rechecked CT or PET-CT manifestation of lesions prior to treatment. The location, largest size and abnormal pulmonary imaging of the lesions were recorded. A 64-row spiral CT with slice thickness of 1.5 mm, 5 mm or high resolution CT was used in all patients and PET-CT was used in a further 36 patients for diagnosis. PET-CT images were obtained 60 min after intravenous injection of FDG. All images were interpreted independently by two experienced physicians; at least one radiologist and another respiratory physician.

 Statistical analysis

SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze the data. Quantitative variables were presented as the mean ± standard deviation whereas qualitative variables were presented as a percentage of the total number. The χ2 test or Fisher's exact test were used to compare clinical characteristics and imaging features between patients with PTB and those with lung cancer. Receiver operating characteristic (ROC) curves were analyzed to determine an SUVmax cut-off that would provide the optimal sensitivity and specificity for individuals undergoing PET-CT. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Clinical features

The clinical characteristics of the 22 patients with PTB are presented in Table I. A total of 18 patients (81.8%) were <60 years old and 12 patients (54.5%) were smokers. A total of 12 patients (54.5%) had a history of diabetes in the 5 years preceding PTB diagnosis. Out of the 81 cases of lung cancer, the most common histological type was primary lung adenocarcinoma (n=69), followed by squamous cell carcinoma (n=9), pulmonary neuroendocrine carcinoma (n=2) and adenosquamous carcinoma (n=1). Furthermore, 32 (38.3%) patients with lung cancer were stage IA, 19 (23.5%) were stage IB, 25 (30.9%) were stage IIA or IIB and 5 (7.4%) were stage III or IV. Out of all patients with lung cancer, 54 (66.7%) underwent examination of levels of the tumor marker values CEA, CYFRA21-1, NSE, CA-125 and SCCAg prior to biopsy or operation. Based on the CT presentation mimicking lung cancer, 27 (33.3%) underwent operation directly without further examination of tumor marker values. Among these 54 cases, 29 (53.7%) abnormal results were obtained for CEA, 26 (48.1%) for CYFRA21-1, 13 (24.1%) for CA-125, 9 (16.7%) for SCCAg and 2 (3.7%) for NSE. Lung tumor markers were also investigated in the 22 patients with PTB, among which 4 patients exhibited abnormal values: 2 abnormal results were obtained for CYFRA21-1, 1 for CEA, 1 for SCCAg and 1 for NSE. The PS results of lung cancer were as follows: 23 (28.4%) lung cancers were 0, 40 (49.4%) were 1 and 18 (22.2%) were 2. The patients with PTB were compared to those with lung cancer and it was determined that the factors associated with PTB were an age <60 years (P=0.003), being male (P=0.025) and the presence of diabetes (P<0.001). No significant differences between patients with lung cancer and those with PTB were observed regarding smoking history (P=0.247).

 Chest CT characteristics of PTB

Chest CT findings demonstrated that PTB lesions involved the left upper lobe in 7 cases (31.8%), left lower lobe in 2 cases (9.1%), right upper lobe in 10 cases (45.5%) and right middle lobe in 3 cases (13.6%). No lesions involved the right lower lobe. The largest size ranged between 1 and 5 cm in diameter and the mean value was 2.51 cm. The suspected malignant signs of lung cancer occurred at PTB lesions and included spiculated margins in 18 cases (81.8%), lobulation in 15 cases (68.2%), blood vessel convergence signs in 4 cases (18.2%), pleural indentation in 8 cases (36.4%), ground-glass shadow in 3 cases (13.6%), cavity in 3 cases (13.6%) and vacuole in 5 cases (22.7%; Table I). Different malignant signs of lung cancer could be detected in a single patient (Fig. 2). Considering the higher risk of malignancy, surgical wedge resection was performed in 17 patients, percutaneous transthoracic needle biopsy in 2 patients and transbronchial lung biopsy in 1 patient. Comparison of the assumed malignancy characteristics in patients with PTB against those with lung cancer (Table II) demonstrated that there were no significant differences between the 2 groups in terms of lobulation, blood vessel convergence signs, pleural indentation and ground-glass opacity (P>0.05). However, there was a significant difference in the frequency of spiculated margins (P=0.002); patients with PTB had a significantly higher frequency of spiculated margins than patients with lung cancer.

 PET-CT findings

Of the 36 patients that underwent PET-CT, 9 patients (25%) were confirmed as PTB and 27 (75%) were diagnosed with lung cancer. Although an SUVmax >2.5 was generally considered to be a diagnostic threshold strongly indicating malignancy, the SUVmax values in all 36 patients were >2.5 (Fig. 3). Comparatively, patients with PTB had a lower mean SUVmax than those with lung cancer; 5.99±2.66 vs. 10.09±5.38 (P=0.036; Table II). An ROC curve with a statistically significant area under the curve was obtained (0.759; 95% confidence interval 0.595–0.924; P=0.021). From the ROC curve, an SUVmax could be obtained that provided optimal sensitivity and specificity for the current study (Fig. 4). With an SUVmax cut-off of 8.45, the sensitivity and specificity of PET-CT in distinguishing between PTB and lung cancer were 63.0 and 88.9%, respectively (Fig. 4). These analyses indicated that an SUVmax cut-off of 8.45 improved the specificity of PET-CT for differentiating between PTB and lung cancer than the conventional SUVmax cut-off value of 2.5.

 Discussion

The present study illustrates the clinical and radiographic presentations of patients with asymptomatic PTB mimicking lung cancer. The clinical characteristics of patients with PTB were compared with those of patients with lung cancer and it was determined that the clinical associated risk factors associated with PTB included age <60 years, being male and having a history of diabetes. The risk factors of PTB have been identified in previous studies and include overcrowding, poverty and undernutrition, alcohol misuse, diabetes, tobacco smoking and immune-suppressive therapy (20,21). Thus, the WHO has recommended screening for diabetes in all patients diagnosed with TB (22). People with diabetes are three times more susceptible to active PTB than those without and it has been demonstrated that diabetes increases the severity of PTB and predicts poor outcomes in patients with PTB (23–25). One of the reasons for increased PTB susceptibility in patients with diabetes is that diabetes adversely affects host innate and adaptive immunity. This impairment of the immune system delays the recruitment of immunocytes, including macrophages and T helper 1 cells, to the lesions and reduces cytokine expression (26). Due to substantial increases in the prevalence of diabetes (27), effectively controlling PTB will become more of a challenge. This means that the coexistence of tuberculosis and diabetes presents a serious threat to global public health. Typical characteristics suggestive of PTB, including cough, hemoptysis, fever, night sweats and chest pain (28), were rare in patients recruited in the current study, making the early diagnosis of PTB more difficult. The results of the present study indicated that the incidence of diabetes in PTB was significantly higher than in lung cancer, thus a diagnosis of PTB should be taken into consideration for people with diabetes even if they present with CT or PET-CT images that suggest the presence of lung cancer.

Tumor markers have been extensively used to distinguish patients with lung cancer from those with benign diseases. High levels of tumor markers are considered to indicate the presence of lung cancer rather than nonmalignant diseases (29). CEA, cancer antigen 125, CYFRA 21-1 and SCCAg are reliable markers in the diagnosis of non-small cell lung cancer whereas pro-gastrin-releasing peptide and NSE are commonly used to diagnose small-cell lung cancer (30–32). However, it has been reported that abnormal concentrations of tumor markers are detected in benign diseases, including PTB (33,34). In the current study, abnormal levels of CEA, CYFRA21-1, NSE and SCCAg were identified in patients with PTB, indicating that positive tumor markers are not specific for lung cancer.

It has been well documented that various morphological features, including spiculated margins, lobulation, blood vessel convergence signs, pleural indentation, ground-glass opacity and cavity with a thick and irregular wall, detected by chest CT scans, are usually associated with malignancy (35–37). By contrast, nodules with smooth margins, bronchus signs and a round shape were considered to be predictors of benign lesions. A recent study analyzing 84 patients diagnosed with PTB by percutaneous transthoracic needle biopsy, identified nodules with spiculated margins in 26 cases and lobulation in 8 (38). In the current study, morphological characteristics of PTB meant that it exhibited one or more signs of malignancy. Furthermore, it was determined that patients with asymptomatic PTB had a significantly higher frequency of spiculated margins than patients with lung cancer. Consequently, there are overlaps between PTB and lung cancer on the chest CT. Although morphological characteristics may be helpful in identifying whether lesions are PTB or lung cancer, the results may not always be conclusive.

As a precise imaging tool, PET-CT has been widely used to distinguish between malignant and benign lesions (39). PET-CT imaging relies on radiopharmaceutical FDG accumulation in increased glucose metabolic areas, so may be used to detect active TB and evaluate the response to anti-tuberculosis therapy in patients (40). Generally, malignant lesions have a significantly higher FDG uptake than benign lesions. The SUVmax cut-off of 2.5 was considered to be a diagnostic threshold for differentiating benign and malignant lesions (41). However, TB has an extensive range of SUVs, which may be due to its varying degree of granulomatous inflammation. It is not uncommon for TB lesions have an SUVmax >2.5, thus false-positive diagnoses may be made, particularly in tuberculosis-endemic areas. In clinical practice, false-positive diagnoses can also result from the presence of other benign conditions including sarcoidosis and rheumatoid nodule (42). The utility of PET-CT in the evaluation of pulmonary lesions has been assessed, and it has been suggested that an SUVmax of 5.0 may be a more appropriate cut-off value in areas with a high prevalence of TB (43). Hence, the diagnostic accuracy of PET-CT in TB-endemic areas was reduced using the conventional SUVmax cut-off value. From the ROC curve constructed in the current study, it was suggested that an SUVmax cut-off of 8.45 may be more effective at distinguishing between PTB and lung cancer in patients. This cut-off value is much higher than the more commonly used threshold of 2.5. Although an SUVmax cut-off value of 8.45 may result in lung cancers with low metabolic activity being falsely reported as PTB, it may prompt clinicians to be more cautious when interpreting results from PET-CT. Although a biopsy is able to differentiate between PTB and lung cancer, it is not technically possible for some patients. To increase the diagnostic accuracy in the assessment of asymptomatic PTB, SUV values as well as other clinical and radiological results should be integrated. After anti-tuberculosis therapy, high SUV values may rapidly decrease and clinical symptoms are ameliorated in PTB patients (44). In contrast, malignant lesions are unlikely to change after anti-tuberculosis therapy. Therefore, a biopsy as well as the clinical and radiological changes resulting from anti-tuberculosis treatment response may be used to differentiate these two similar diseases.

In conclusion, patients with asymptomatic PTB mimicking lung cancer usually exhibit abnormal chest CT presentation and increased glucose uptake, which is extremely similar to lung cancer. Compared with lung cancer, the factors associated with asymptomatic PTB include an age of <60 years, being male, having diabetes, spiculated margins and a lower SUVmax. The optimal cut-off level was SUVmax 8.45 for discriminating between asymptomatic PTB and lung cancer. Comprehensively considering the associated risk factors and recognizing the various imaging manifestations of this uncommon PTB may increase the diagnostic accuracy of asymptomatic PTB. An increased threshold of SUVmax may markedly improve the specificity of PET-CT of diagnosing PTB in TB-endemic area and further multicenter studies involving larger samples sizes are required.

 Acknowledgements

The present study was supported by the National Science and Technology Major Project of China (grant no. 2015ZX09J15105-004). The authors wish to thank all of the patients involved in the present study.

 References DhedaKBarryCEIIIMaartensGTuberculosisLancet38712111226201610.1016/S0140-6736(15)00151-826377143 Global tuberculosis report 2015World Health OrganizationGeneva2014 GetahunHMatteelliAChaissonRERaviglioneMLatent mycobacterium tuberculosis infectionN Engl J Med37221272135201510.1056/NEJMra140542726017823 BurrillJWilliamsCJBainGConderGHineALMisraRRTuberculosis: A radiologic reviewRadiographics2712551273200710.1148/rg.27506517617848689 LenaertsABarryCEIIIDartoisVHeterogeneity in tuberculosis pathology, microenvironments and therapeutic responsesImmunol Rev264288307201510.1111/imr.1225225703567 ChenWZhengRZengHZhangSHeJAnnual report on status of cancer in China, 2011Chin J Cancer Res27212201510.1186/s40880-015-0001-225717220 ZhengRZengHZuoTZhangSQiaoYZhouQChenWLung cancer incidence and mortality in China, 2011Thorac Cancer79499201610.1111/1759-7714.1228626816543 ZhouCLung cancer molecular epidemiology in China: Recent trendsTransl Lung Cancer Res3270279201425806311 PitlikSDFainsteinVBodeyGPTuberculosis mimicking cancer-a reminderAm J Med76822825198410.1016/0002-9343(84)90993-86720729 BoyaciHBasyigitIBarisSAPositron emission tomography/computed tomography in cases with tuberculosis mimicking lung cancerBraz J Infect Dis17267269201310.1016/j.bjid.2012.05.00523474190 HammenITuberculosis mimicking lung cancerRespir Med Case Rep164547201526744652 ShettyNNoronhaVJoshiARangarajanVPurandareNMohapatraPRPrabhashKDiagnostic and treatment dilemma of dual pathology of lung cancer and disseminated tuberculosisJ Clin Oncol32e7e9201410.1200/JCO.2012.46.066724395843 PrapruttamDHedgireSSManiSEChandramohanAShyamkumarNKHarisinghaniMTuberculosis-the great mimickerSemin Ultrasound CT MR35195214201410.1053/j.sult.2014.02.00224929261 LeeCKangKHKohYChangJChungHSParkSKYooKSongJSCharacteristics of lung cancer in Korea, 1997Lung Cancer301522200010.1016/S0169-5002(00)00126-411008006 ShielsMSAlbanesDVirtamoJEngelsEAIncreased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention studyCancer Epidemiol Biomarkers Prev20672678201110.1158/1055-9965.EPI-10-116621335509 WuCYHuHYPuCYHuangNShenHCLiCPChouYJPulmonary tuberculosis increases the risk of lung cancer: A population-based cohort studyCancer117618624201110.1002/cncr.2561620886634 TravisWDBrambillaEBurkeAPMarxANicholsonAGWHO classification of tumours of the lung, pleura, thymus and heart4thInternational Agency for Research on CancerLyon9962015 EdgeSBComptonCCThe American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol1714711474201010.1245/s10434-010-0985-420180029 BagleySJKothariSAggarwalCBaumlJMAlleyEWEvansTLKostevaJACiunciCAGabrielPEThompsonJCPretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerLung Cancer10617201710.1016/j.lungcan.2017.01.01328285682 TheronGJenkinsHECobelensFAbubakarIKhanAJCohenTDowdyDWData for action: Collection and use of local data to end tuberculosisLancet38623242333201510.1016/S0140-6736(15)00321-926515676 BatesMNKhalakdinaAPaiMChangLLessaFSmithKRRisk of tuberculosis from exposure to tobacco smoke: A systematic review and meta-analysisArch Intern Med167335342200710.1001/archinte.167.4.33517325294 World Health Organization (WHO): Collaborative Framework for Care and Control of Tuberculosis and DiabetesWHO Guidelines approved by the Guidelines Review CommitteeWHO, Geneva2011 BakerMAHarriesADJeonCYHartJEKapurALönnrothKOttmaniSEGoonesekeraSDMurrayMBThe impact of diabetes on tuberculosis treatment outcomes: A systematic reviewBMC Med981201110.1186/1741-7015-9-8121722362 HongguangCMinLShiwenJFanghuiGShaopingHTiejieGNaLZhiguoZImpact of diabetes on clinical presentation and treatment outcome of pulmonary tuberculosis in BeijingEpidemiol Infect143150156201510.1017/S095026881400079X24717600 JeonCYMurrayMBDiabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studiesPLoS Med5e152200810.1371/journal.pmed.005018118630984 MartinezNKornfeldHDiabetes and immunity to tuberculosisEur J Immunol44617626201410.1002/eji.20134430124448841 ShawJESicreeRAZimmetPZGlobal estimates of the prevalence of diabetes for 2010 and 2030Diabetes Res Clin Pract87414201010.1016/j.diabres.2009.10.00719896746 NguyenMVJenny-AvitalERBurgerSLeibertEMAchkarJMClinical and radiographic manifestations of sputum culture-negative pulmonary tuberculosisPLoS One10e0140003201510.1371/journal.pone.014000326448182 OkamuraKTakayamaKIzumiMHaradaTFuruyamaKNakanishiYDiagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancerLung Cancer804549201310.1016/j.lungcan.2013.01.00223352032 MolinaRFilellaXAugéJMFuentesRBoverIRifaJMorenoVCanalsEViñolasNMarquezATumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factorsTumour Biol24209218200310.1159/00007443214654716 CedrésSNuñezILongoMMartinezPChecaETorrejónDFelipESerum tumor markers CEA, CYFRA21-1 and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)Clin Lung Cancer12172179201110.1016/j.cllc.2011.03.01921663860 ShibayamaTUeokaHNishiiKKiuraKTabataMMiyatakeKKitajimaTHaradaMComplementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC)Lung Cancer326169200110.1016/S0169-5002(00)00205-111282430 MolinaRAugeJMFilellaXViñolasNAlicarteJDomingoJMBallestaAMPro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: Comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancerAnticancer Res2517731778200516033098 KagohashiKSatohHKurishimaKKadonoKIshikawaHOhtsukaMSekizawaKSquamous cell carcinoma antigen in lung cancer and nonmalignant respiratory diseasesLung186323326200810.1007/s00408-008-9108-418663529 SiegelmanSSKhouriNFLeoFPFishmanEKBravermanRMZerhouniEASolitary pulmonary nodules: CT assessmentRadiology160307312198610.1148/radiology.160.2.37261053726105 ZwirewichCVVedalSMillerRRMüllerNLSolitary pulmonary nodule: High-resolution CT and radiologic-pathologic correlationRadiology179469476199110.1148/radiology.179.2.20142942014294 WoodringJHFriedAMSignificance of wall thickness in solitary cavities of the lung: A follow-up studyAJR Am J Roentgenol140473474198310.2214/ajr.140.3.4736600536 ChooJYLeeKYKimMYKangEYOhYWLeeSHSeoBKJeBKPulmonary tuberculosis confirmed by percutaneous transthoracic needle biopsy: Analysis of CT findings and review of correlations with underlying lung diseaseBalkan Med J31208213201410.5152/balkanmedj.2014.1318725625018 DabrowskaMKrenkeRKorczynskiPMaskey-WarzechowskaMZukowskaMKunikowskaJOrłowskiTChazanRDiagnostic accuracy of contrast-enhanced computed tomography and positron emission tomography with 18-FDG in identifying malignant solitary pulmonary nodulesMedicine (Baltimore)94e666201510.1097/MD.000000000000066625881842 ChenRYDoddLELeeMParipatiPHammoudDAMountzJMJeonDZiaNZahiriHColemanMTPET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosisSci Transl Med6265ra166201410.1126/scitranslmed.300950125473034 SimYTGohYGDempseyMFHanSPoonFWPET-CT evaluation of solitary pulmonary nodules: Correlation with maximum standardized uptake value and pathologyLung191625632201310.1007/s00408-013-9500-624013495 GouldMKDoningtonJLynchWRMazzonePJMidthunDENaidichDPWienerRSEvaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest143(5 Suppl)e93Se120S201310.1378/chest.12-235123649456 du ToitRShawJAIrusenEMvon Groote-BidlingmaierFWarwickJMKoegelenbergCFThe diagnostic accuracy of integrated positron emission tomography/computed tomography in the evaluation of pulmonary mass lesions in a tuberculosis-endemic areaS Afr Med J10510491052201510.7196/SAMJ.2015.v105i12.1030026792164 VerbeeckRKGüntherGKibuuleDHunterCRennieTWOptimizing treatment outcome of first-line anti-tuberculosis drugs: The role of therapeutic drug monitoringEur J Clin Pharmacol72905916201610.1007/s00228-016-2083-427305904

Study flow chart.

Representative chest computed tomography presentations of asymptomatic pulmonary tuberculosis mimicking lung cancer. Lesions in the 4 cases (from 4 different patients) exhibited the suspected malignant signs of lung cancer including (A) spiculated margins, pleural indentation (B) lobulation, spiculated margins, pleural indentation (C) blood vessel convergency, spiculated margain, pleural indentation (D) pleural indentation and lobulation.

PET-CT imaging of asymptomatic pulmonary tuberculosis mimicking lung cancer. PET-CT revealed a 2.3×1.3 cm lesion with malignancy features and the SUVmax was 7.7 in the right upper lobe. PET-CT, 18F-fludeoxyglucose-positron emission tomography-computer tomography; SUVmax, maximum standard uptake value.

The ROC curve represented the capability of SUVmax to differentiate PTB from lung cancer. ROC, receiver operating characteristic; SUVmax, the maximum standard uptake value.

Clinical characteristics and imaging features of the 22 patients with PTB.

No./age/sex Smoking (years/cigarettes per day) Diabetes Largest size (cm) Location of lesion Type of biopsy CT presentation PET (SUVmax)
1/41/M 20/20 Yes     2.8 RUL Pulmonary lobectomy Ground-glass shadow, spiculated margin, lobulation, vacuole     2.65
2/41/M 20/40 Yes     2.5 RUL Pulmonary lobectomy Spiculated margin, vacuole     8.4
3/64/M 20/60 Yes 5 RUL Pulmonary lobectomy Spiculated margin, lobulation, pleural indentation –
4/51/M 30/50 Yes     2.5 RUL Pulmonary lobectomy Spiculated margin, lobulation –
5/43/F No No     2.6 RML Pulmonary lobectomy Spiculated margin, blood vessel convergency –
6/50/M No Yes     1.2 LUL PTNB Ground-glass shadow –
7/59/M 30/20 Yes 2 LUL Pulmonary lobectomy Pleural indentation, vacuole –
8/55/F No No     1.6 RUL TBLB Spiculated margin, lobulation 10.9
9/61/M 15/40 Yes     3.2 RML Pulmonary lobectomy Spiculated margin, lobulation, pleural indentation, cavity –
10/57/M No Yes     2.3 RUL Pulmonary lobectomy Spiculated margin, lobulation, pleural indentation     7.7
11/68/M 50/20 Yes 4 LUL Pulmonary lobectomy Spiculated margin, lobulation, pleural indentation –
12/39/M No No     1.3 LUL Pulmonary lobectomy Spiculated margin, lobulation     5.4
13/72/M No No 1 RML Pulmonary lobectomy Spiculated margin, lobulation     3.16
14/63/M 35/20 Yes     1.8 LUL Pulmonary lobectomy Spiculated margin, pleural indentation, blood vessel convergency –
15/51/F No Yes 3 LUL Pulmonary lobectomy Spiculated margin, lobulation     4.2
16/59/M No Yes     2.5 LLL Pulmonary lobectomy Spiculated margin, lobulation, cavity, ground-glass shadow –
17/56/M 40/20 No     1.5 LLL Pulmonary lobectomy Spiculated margin, lobulation, blood vessel convergency –
18/41/F 40/20 No     3.5 RUL Pulmonary lobectomy Spiculated margin, vacuole     6.5
19/59/M No No     2.7 RUL PTNB Spiculated margin, lobulation, cavity –
20/36/F No No     2.4 RUL Pulmonary lobectomy Spiculated margin, pleural indentation –
21/47/M 10/20 No     3.5 RUL Pulmonary lobectomy Lobulation, vacuole –
22/57/M 20/40 No     2.5 LUL Pulmonary lobectomy Lobulation, blood vessel convergency, pleural indentation 5.02

No, patient number; M, male; F, female; SUVmax, maximum standard uptake value; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle lobe; PTNB, percutaneous transthoracic needle biopsy; TBLB, transbronchial lung biopsy; PET, 18F-fludeoxyglucose-positron emission tomography.

Clinical and radiological finding in patients with PTB vs. those with lung cancer.

Total, no. (%) Tuberculosis, no. (%) Lung cancer, no. (%) P-value
No. 103 22 81
Age, years 0.003a
  <60   55 18 37
  ≥60   48   4 44
Sex 0.025a
  Male   58 17 41
  Female   45   5 40
Smoking history 0.247
  Smoker   45 12 33
  Never smoked   58 10 48
Underlying diseases <0.001a
  Diabetes   25 12 13
  Non-diabetes   78 10 68
Location of lesion 0.175
  Upper lobe   67 17 50
  Others   36   5 31
Largest size (cm) 0.210
  <2   40   6 34
  ≥2   63 16 47
CT presentation
  Spiculated margin   54 18 36 0.002a
  Lobulation   63 15 48 0.446
  Ground-glass shadow   31   3 28 0.058
  Pleural indentation   38   8 30 0.922
  Blood vessel convergency   25   4 21 0.452
  Cavity   8   3   5 0.477
  Vacuole   13   5   8 0.212
PET (SUVmax)
  Mean ± SD 9.06±5.13 5.99±2.66 10.09±5.38 0.036a

P<0.05 patients with PTB vs. patients with lung cancer. No, number; PTB, pulmonary tuberculosis; CT, computed tomography; PET, 18F-fludeoxyglucose-positron emission tomography/computer tomography; SUVmax, maximum standard uptake value; SD, standard deviation.